Remove Diabetes Remove Labelling Remove White Paper
article thumbnail

Why security-first design is the fix to stalling AI pilot tools

pharmaphorum

Skip to main content Wednesday 2 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

The drug was approved to treat type 2 diabetes mellitus in May. High rates of obesity place a major burden on healthcare systems as the condition is associated with many major health complications like type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and other bodily dysfunctions. Anti-obesity therapeutic landscape.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Bayer’s Eylea market grip set to slip as Alvotech biosimilar closes in

Pharmaceutical Technology

Eylea is approved in four indications in Europe: the treatment of ‘wet’ age-related macular degeneration (AMD), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DME) and visual impairment due to myopic choroidal neovascularisation (myopic CNV).

article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

The drug was approved to treat type 2 diabetes mellitus in May. High rates of obesity place a major burden on healthcare systems as the condition is associated with many major health complications like type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and other bodily dysfunctions. Anti-obesity therapeutic landscape.

article thumbnail

CMO Moves: Regulatory catalysts for therapy manufacturing -January

Pharmaceutical Technology

In the same month, the EMA expanded the label of Gilead Sciences’ Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) to include its use for virologically suppressed HIV-positive children. The EMA also expanded the label of AbbVie’s Skyrizi (risankizumab) to include its use to treat moderate-to-severe Crohn’s disease.

article thumbnail

Africa: Unleashing the potential of the new superpower in clinical trials

Pharmaceutical Technology

Rates of non-communicable diseases such as hypertension, cardiovascular disease, chronic respiratory diseases, diabetes, and cancers are also considered high throughout Africa. Consequently, there are relatively small patient pools for non-communicable diseases such as cancer, diabetes, heart disease, and Alzheimer’s.

article thumbnail

Dawn of a new indication: how to study drugs for aging 

Pharmaceutical Technology

For example, in the Targeting Aging with Metformin (TAME) Trial , a series of six-year studies, the diabetes drug metformin will be studied for its effects in preventing age-related conditions such as cardiovascular disease, cancer, impaired cognition, and mortality. Kaeberlein says efforts to label aging as an indication may be misguided. “It’s

Labelling 145